CYTK Q3 2024 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$463,000+22.5% YoY

Gross Profit

-$84M-18174.7% margin

Operating Income

-$141M-30410.6% margin

Net Income

-$161M-34674.9% margin

EPS (Diluted)

$-1.36

QoQ Revenue Growth

+85.9%

Cash Flow

Operating Cash Flow

-$102M

Free Cash Flow

-$104M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.4B

Stockholders' Equity

-$14M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$463,000	$378,000	+22.5%
Gross Profit	-$84M	-$82M	-2.4%
Operating Income	-$141M	-$122M	-15.2%
Net Income	-$161M	-$129M	-24.0%

Revenue Segments

Research And Development

$463,000100%